Click here to learn more.

ROCKVILLE, MD-Advances in evidence-based obesity medications and treatment options are critical for the millions of individuals living with the chronic disease. The Obesity Society is encouraged by the development of new options that are effective, safe, and convenient for consumers. Last week, results released for the ACHIEVE-1 Phase 3 clinical trial suggest that a new medication, Orforglipron, an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken once daily led to an average weight loss of 7.9% in individuals with diabetes and impaired glycemic control. Researchers noted that participant weight loss had not yet plateaued hinting that additional weight [...]

Rockville, Md. – The Obesity Society is disappointed with the decision made by the Centers for Medicare and Medicaid Services (CMS) to continue its policy that restricts access to safe and effective obesity medications. The announcement that CMS will reject Part D coverage of obesity medications and application to the Medicaid program in a final rule last week has both clinical and ethical implications for those living with the chronic disease and the providers who treat them. “While there are proven treatments including obesity medications, most Americans and those on Medicare, are not able to access interventions other than [...]

March 19, 2025 — Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across the healthcare continuum, urging the agency to enforce federal regulations around compounding following the recent resolution of GLP-1 medicine shortages. Among the signatories include: the Alliance for Women’s Health & Prevention, the Association of Black Cardiologists, the National Hispanic Medical Association and the National Consumers League. The letter follows recent announcements from the FDA that Eli Lilly’s tirzepatide, marketed as Zepbound for weight loss and [...]

ROCKVILLE, MD – The Obesity Society (TOS) acknowledges the U.S. Food and Drug Administration's (FDA) recent announcement declaring the end of shortages for Novo Nordisk's Wegovy and Ozempic; two critical medications in the treatment of obesity and diabetes. This development signifies a pivotal advancement in patient care, ensuring broader access to these essential, FDA-approved therapies. This announcement follows the agency’s December 19th decision that Eli Lilly’s tirzepatide, marketed as Zepbound for weight loss, was no longer in shortage and it would give compounders 60 to 90 days before putting a stop to their production of the copycat GLP-1s. During [...]

Rockville, Md. -- A Super Bowl advertisement by Hims & Hers, a consumer health and wellness platform, will mislead viewers by excluding any information about the overall risks and side effects of compounded drugs. The ad emphasizes the role of the food and health system in the obesity epidemic and fails to include any specific information about the potential risks and side effects of Hims’ drugs being marketed to consumers. “The Obesity Society advocates for access to safe and effective obesity medications that have been proven to improve health outcomes and quality of life,” stated President Marc-Andre Cornier, MD, [...]

ROCKVILLE, Md. -- The Obesity Society (TOS) applauds the work of The Lancet Diabetes & Endocrinology Commission on Diagnostic Criteria of Clinical Obesity to refine the definition of obesity and establish a framework for diagnosing other chronic diseases caused by excess adiposity. Several prominent experts in obesity and related metabolic diseases who are members of TOS served on the Commission offering scientific and clinical expertise.  The Lancet Commission framework aims to address challenges with the traditional definition and diagnosis of obesity that impede clinical practice and access to care for people living with obesity. Given the complexities of obesity, [...]

Washington, DC—The Obesity Care Advocacy Network (OCAN), and more than 70 other patient advocacy organizations across the spectrum of related obesity co-morbidities, issued a statement urging the Trump administration to finalize the proposed CMS rulemaking to align coverage policy for Medicare and Medicaid to reflect that obesity is a chronic disease. The statement urges that if action is not taken, the total number of adults with overweight or obesity could reach 213 million. To achieve making America healthier, obesity must be addressed, treated and managed effectively. More excerpts from the statement are below: “Obesity is a treatable chronic disease [...]

SAN ANTONIO, Tx - Cancer patients need a lot of drugs—immunotherapies, chemotherapies, and anti-infectives. But new research at ObesityWeek® on Nov. 3, 2024, shows clinicians may not have all the information they need to use these drugs safely if the patient has obesity. For example, about half of U.S. oncologists are unaware of prolonged risks for interactions with a common antifungal drug and cancer drugs in persons with obesity. Currently, the FDA does not require medications seeking approval to be tested in people with obesity (PwO), and drug manufacturers often exclude PwO from clinical trials, despite the fact that [...]

Rockville, Maryland, August 30, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE: October 18, 2024 The Obesity Society (“TOS”), the leading professional society focused on obesity science, treatment, and prevention, is pleased to welcome Sherlyn Celone-Arnold, MS, as Chief of Strategy and Professional Development. As Chief of Strategy and Professional Development, Ms. Celone-Arnold will work in partnership with TOS Leadership, the Executive Committee, and Governing Board. She will help drive the strategic vision for the organization, enhance value to its members, and pioneer innovative educational solutions for clinicians, researchers, allied healthcare professionals, and patients in the field of obesity medicine [...]